Summit Trail Advisors LLC Increases Stake in GSK plc (NYSE:GSK)

Summit Trail Advisors LLC increased its holdings in GSK plc (NYSE:GSK) by 19.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,834 shares of the pharmaceutical company’s stock after purchasing an additional 1,457 shares during the quarter. Summit Trail Advisors LLC’s holdings in GSK were worth $302,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Eastern Bank purchased a new stake in shares of GSK during the third quarter valued at approximately $26,000. Crews Bank & Trust bought a new stake in GSK during the 4th quarter valued at $26,000. ST Germain D J Co. Inc. boosted its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. grew its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Finally, Concord Wealth Partners increased its position in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares during the period. 15.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GSK. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley started coverage on GSK in a research note on Wednesday. They set an “equal weight” rating on the stock. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Performance

Shares of GSK stock opened at $36.15 on Thursday. The business has a fifty day simple moving average of $34.31 and a two-hundred day simple moving average of $37.51. The firm has a market capitalization of $74.92 billion, a P/E ratio of 22.74, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a current ratio of 0.78, a quick ratio of 0.53 and a debt-to-equity ratio of 1.12. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, equities analysts forecast that GSK plc will post 4.07 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.35%. The ex-dividend date is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is 93.08%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.